Join the Filgrastim group to help and get support from people like you.
Filgrastim News
Related terms: Filgrastim-sndz
FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen
July 01, 2024 Tanvex BioPharma, Inc. (TWSE: 6541) announced that The U.S. Food and Drug Administration (FDA) had completed their review of our submission of Nypozi (TX01) and approved the biologics...
FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
PISCATAWAY, N.J.--(BUSINESS WIRE)-- March 2, 2022 Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for...
FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 20, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen1...
FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)
March 6, 2015 – The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived...
FDA Approves Teva’s Granix (tbo-filgrastim) Injection for Self-Administration
JERUSALEM, December 23, 2014--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Granix (tbo-filgrastim)...
FDA Approves Tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients
August 29, 2012 – The U.S. Food and Drug Administration today approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, ...
Further information
Related condition support groups
Neutropenia Associated with Chemotherapy